Envoy Medical

09/01/2026

September is Healthy Aging Month—a reminder that aging well encompasses more than physical health.

Hearing health plays an important role in staying connected. Participating in conversations, nurturing meaningful relationships, and engaging with the people and world around us can support overall well-being and quality of life.

What helps you stay connected as you age?

08/14/2026

Momentum continues at Envoy Medical (NASDAQ: COCH).

We reported our Corporate and Financial Highlights for the Quarter ending June 30, 2026, including reaching an important milestone with the submission of the first module of our FDA Premarket Approval (PMA) application for the investigational Acclaim® Cochlear Implant. We also noted continued advancement of our pivotal clinical trial and shared positive 12-month clinical data on the first 10 participants in Stage 1.

We remain focused on advancing what we believe could become the first fully implanted cochlear implant available to patients.

We are committed to pushing hearing technology beyond the status quo and improving quality of life for people with hearing loss.

Learn more here: https://hubs.li/Q04t37sj0

CAUTION: The fully implanted Acclaim Cochlear Implant is an investigational device. Limited by Federal (or United States) law to investigational use.

07/23/2026

Clinical Momentum Update!

Envoy Medical® Inc. (NASDAQ: COCH) has now reached the 3-month visit milestone for all 56 patients enrolled in the pivotal trial of the investigational Acclaim® fully implanted cochlear implant.

This milestone reflects continued progress toward a potential FDA PMA submission and our broader mission to advance fully implanted hearing technology.

We are grateful to the patients, investigators, and clinical teams helping move this important work forward.

Learn more here: https://hubs.li/Q04qw4Zv0

CAUTION The fully implanted Acclaim Cochlear Implant is an investigational device. Limited by Federal (or United States) law to investigational use.

07/14/2026

For people following progress in hearing implant technology, we’re encouraged to share a 12-month update from the first 10 participants in Stage 1 of our pivotal clinical trial evaluating the investigational, fully implanted Acclaim® cochlear implant.

At 12 months, CNC word recognition improved to 53.2%, up from 15.2% before implantation, and no serious adverse events were reported through 12 months for these 10 participants.

Stage 2 is also moving forward as planned. All Stage 2 participants have completed their 1-month visit, and many have already reached their 3- and 6-month follow-up visits. We expect all Stage 2 participants to complete 12-month data collection by early Q2 2027, followed by a PMA submission to the FDA anticipated a few months later.

As CEO Brent Lucas shared, "While the study remains ongoing and these interim results are preliminary, these data reinforce our conviction that the future of cochlear implants is in fully implanted devices using Invisible Hearing® technology".

Learn more here: https://hubs.li/Q04pwj3n0

CAUTION: The fully implanted Acclaim Cochlear Implant is an investigational device. Limited by Federal (or United States) law to investigational use.

07/04/2026

As you celebrate the Fourth of July, don't forget to protect your hearing.

Fireworks can exceed 150dB - loud enough to cause permanent hearing damage. Wearing hearing protections and keeping a safe distance can help preserve your hearing for years to come.

Wishing everyone a safe and happy independence day!

07/01/2026

We are excited to announce submission of the first module of our Modular PMA application to the FDA for our investigational Breakthrough Device-designed Acclaim® cochlear implant.

This marks the first step in a modular submission strategy that allows completed sections of the application to be submitted for FDA review over time to support earlier engagement and review with a final clinical module submission being targeted for Q2 2027.

We believe this approach gives greater visibility into our progress as we continue our strategy to advance fully implanted hearing solutions.

Learn more here: https://hubs.li/Q04n72lh0

CAUTION The fully implanted Acclaim Cochlear Implant is an investigational device. Limited by Federal (or United States) law to investigational use.

06/30/2026

Healthy Vision Month is a reminder to protect sight—but vision doesn’t work alone.

If you have vision loss, you rely on hearing.

If you have hearing loss, you rely on vision.
Now imagine losing both.

That’s dual sensory loss—and it changes everything.
- You can’t see who is speaking.
- You can’t hear what they are saying.
- You lose the ability to use one sense to compensate for the other.

It’s not just harder—it’s disorienting. And the impact compounds quickly:

- Higher risk of falls
- Increased isolation
- Greater cognitive load
- Loss of independence

Healthy vision isn’t just about the eyes.
It’s about how vision connects with the rest of your senses to keep you oriented, engaged, and safe.
When one sense is affected, the other often becomes the fallback.
When both are affected, that safety net disappears.

This Healthy Vision Month, don’t stop at vision.
Think about hearing, too.

06/22/2026

We’re pleased to share that Brent Lucas, CEO of Envoy Medical (NASDAQ: COCH), will present at two investor events on June 25, 2026: the Virtual Life Sciences Investor Forum and the Biotech Webull Webinar Panel.

As a hearing health company pioneering fully implanted hearing solutions, Envoy Medical remains focused on advancing innovation that may improve access, usability, compliance, and quality of life for people with hearing loss.

We invite investors and interested stakeholders to tune in on June 25 to learn more about our progress and vision.

Learn more here: https://hubs.li/Q04m8X2H0



CAUTION The fully implanted Acclaim Cochlear Implant is an investigational device. Limited by Federal (or United States) law to investigational use.

06/15/2026

Don't miss Our CEO Brent Lucas presenting at the Planet Microcap Conference this week in Las Vegas, Nevada. The event is free, and you can participate in the presentation virtually.

To sign up for the Webcast: https://hubs.li/Q04lsx6N0

CAUTION The fully implanted Acclaim Cochlear Implant is an investigational device. Limited by Federal (or United States) law to investigational use.

As always, future milestones remain subject to development, regulatory, and ex*****on of progress.

06/12/2026

Millions of adults in the US qualify for cochlear implants, yet many remain untreated due to reluctance to wear a traditional external device on or around the ear.

At Envoy Medical (NASDAQ: COCH), we're working to change that. Our investigational Acclaim® cochlear implant is a first-of-its-kind, fully implanted hearing device, placed entirely beneath the skin, leveraging the ear's natural anatomy to capture sound.

Our Invisible Hearing® technology is designed to support patients who are not interested in conventional systems. We believe that's a significant, underpenetrated market opportunity.

Envoy CEO Brent Lucas shares an update on our pivotal study progress and PMA submission timeline: https://hubs.li/Q04lcGLx0

CAUTION The fully implanted Acclaim Cochlear Implant is an investigational device. Limited by Federal (or United States) law to investigational use.

Envoy Medical (NASDAQ: COCH) is advancing development of its Acclai...